Spoken Alpha
Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc. develops and commercializes biopharmaceutical products for kidney disease. The company markets two approved drugs: Vafseo (vadadustat), an oral treatment for anemia in dialysis patients approved in 2024, and Auryxia (ferric citrate), which treats high phosphorus levels and iron deficiency anemia in kidney disease patients.
Akebia Therapeutics, Inc is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $251.2M market cap.
Most recent reported earnings: Q3 FY2026 (Nov 8, 2026).
19 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for AKBA.
$ curl https://api.spokenalpha.com/v1/companies/AKBAFAQ
Spoken Alpha indexes AKBA's earnings call transcripts at https://spokenalpha.com/companies/AKBA. Each call links to attributed speakers and parsed analyst Q&A. Akebia Therapeutics, Inc.'s own investor relations page is at https://ir.akebia.com/.
Akebia Therapeutics, Inc. (AKBA) held its most recent earnings call on 2026-08-05, covering fiscal Q2 2026.
Akebia Therapeutics, Inc. (AKBA) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-08 | — | $-0.03 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-04 | $-0.02 | $-0.03 | +33.3% | $49.1M | — | — | EODHD |
| Q1 FY2026 | 2026-05-06 | $-0.03 | $-0.02 | -50.0% | $53.5M | — | — | EODHD |
| Q4 FY2025 | 2026-02-25 | $-0.05 | $-0.03 | -66.7% | $57.6M | — | — | EODHD |
| Q3 FY2025 | 2025-11-09 | $0.00 | $-0.04 | +100.0% | $58.8M | — | — | EODHD |
| Q2 FY2025 | 2025-08-06 | $0.03 | $-0.02 | +100.0% | $62.5M | — | — | EODHD |
| Q1 FY2025 | 2025-05-07 | $0.02 | $-0.04 | +100.0% | $57.3M | — | — | EODHD |
| Q4 FY2024 | 2025-03-11 | $-0.10 | $-0.07 | -33.3% | $46.5M | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $-0.10 | $-0.05 | -100.0% | $37.4M | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $-0.04 | $-0.05 | +20.0% | $43.6M | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $-0.08 | $-0.09 | +11.1% | $32.6M | — | — | EODHD |
| Q4 FY2023 | 2024-03-13 | $0.00 | $-0.04 | +100.0% | $56.2M | — | — | EODHD |
| Q3 FY2023 | 2023-11-07 | $-0.08 | $-0.08 | 0.0% | $42.0M | — | — | EODHD |
| Q2 FY2023 | 2023-08-24 | $-0.06 | $-0.02 | -100.0% | $56.4M | — | — | EODHD |
| Q1 FY2023 | 2023-05-07 | $-0.14 | $-0.15 | +6.7% | $40.0M | — | — | EODHD |
| Q4 FY2022 | 2023-03-08 | $-0.04 | $-0.19 | +79.0% | $55.2M | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $-0.29 | $-0.12 | -100.0% | $48.7M | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $0.23 | $-0.33 | +100.0% | $126.4M | — | — | EODHD |
| Q1 FY2022 | 2022-05-08 | $-0.35 | $-0.29 | -20.7% | $61.7M | — | — | EODHD |
| Q4 FY2021 | 2022-02-28 | $-0.40 | $-0.33 | -21.2% | $57.7M | — | — | EODHD |
Source: EODHD. AKBA reported actuals as published; sparse fields render as —.